Literature DB >> 3121601

Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids.

J Baudier1, R D Cole.   

Abstract

Calcium/calmodulin (CaM)-dependent protein kinases isolated from bovine and rat brains phosphorylate the microtubule-associated tau protein in the mode that shifts the mobility of tau in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (mode I). This mode of tau phosphorylation is the one that occurs abnormally in Alzheimer's lesions. Purified tau protein in solution can be phosphorylated by the Ca2+/CaM kinases maximally to about 50% of the total tau protein. Incorporation of one phosphate group per mol of tau is sufficient to shift the protein to a slower migrating electrophoretic band. Additional phosphate incorporation into the shifted tau proteins can occur depending on protein kinase concentration. In the presence of phosphatidylserine, tau proteins were phosphorylated to an extent of 100% at a tau: phosphatidylserine ratio of 20. Phosphatidylethanolamine also stimulated tau phosphorylation by Ca2+/CaM kinase and phosphatidylinositol was found to be a potent inhibitor of tau protein phosphorylation. The direct observation that tau proteins interact with phospholipids such as phosphatidylethanolamine and phosphatidylinositol, resulting in a smearing of the protein band on sodium dodecyl sulfate-gel electrophoresis, supports the possibility that tau protein may interact with phospholipid membranes in vivo and that tau protein phosphorylation could be modulated by the phospholipid composition of the membranes with which tau interacts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121601

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  S100beta interaction with tau is promoted by zinc and inhibited by hyperphosphorylation in Alzheimer's disease.

Authors:  W H Yu; P E Fraser
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

Review 2.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

3.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

4.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

5.  Quantitative measurement of in vivo phosphorylation states of Cdk5 activator p35 by Phos-tag SDS-PAGE.

Authors:  Tomohisa Hosokawa; Taro Saito; Akiko Asada; Kohji Fukunaga; Shin-Ichi Hisanaga
Journal:  Mol Cell Proteomics       Date:  2010-01-23       Impact factor: 5.911

6.  Doxorubicin affects tau protein metabolism in human neuroblastoma cells.

Authors:  A Argasinski; H Sternberg; B Fingado; P Huynh
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

7.  Comparison of the phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases.

Authors:  T J Singh; I Grundke-Iqbal; B McDonald; K Iqbal
Journal:  Mol Cell Biochem       Date:  1994-02-23       Impact factor: 3.396

8.  Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP.

Authors:  L M Fleming; G V Johnson
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

9.  A galactose-dependent cmd1 mutant of Saccharomyces cerevisiae: involvement of calmodulin in nuclear division.

Authors:  Y Ohya; Y Anraku
Journal:  Curr Genet       Date:  1989-02       Impact factor: 3.886

10.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Authors:  Yang Yu; Xiaoqin Run; Zhihou Liang; Yi Li; Fei Liu; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-01-13       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.